3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
145
Neoplasm Metastasis
16
Advanced Breast Cancer
9
Neoplasms
8
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
5
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lung Neoplasms
2
Hyperglycemia
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Colorectal Neoplasms
2
Carcinoma, Lobular
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Recurrent Uterine Corpus Carcinoma
1
Neoplastic Cells, Circulating
1
Interventions
Carboplatin
36
Pemetrexed
28
Bevacizumab
26
Cisplatin
24
Paclitaxel
22
Gemcitabine
20
Radiotherapy
18
Docetaxel
18
Erlotinib Hydrochloride
15
Gefitinib
11
pembrolizumab
6
Cetuximab
6
capmatinib
5
Surgical Procedures, Operative
5
Radiosurgery
5
aflutinib
4
Vinorelbine
4
Taxes
4
Platinum
4
Nivolumab
4
Metformin
4
pegfilgrastim
3
durvalumab
3
ceritinib
3
apatinib
3
Sorafenib
3
Radiation
3
Neoadjuvant Therapy
3
Magnetic Resonance Spectroscopy
3
tislelizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma of Lung
×
Fulvestrant
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled